Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Gastroenterology

Treatment Pathways: Managing Your EGE

At a Glance

Treatment for Eosinophilic Gastroenteritis (EGE) is highly personalized, focusing on dietary elimination to remove trigger foods or medications like corticosteroids to calm the immune system. Emerging biologic therapies also offer new hope for severe or chronic EGE cases.

Treating Eosinophilic Gastroenteritis (EGE) is a highly personalized process. Because every patient’s trigger and disease depth are different, there is no “one-size-fits-all” approach [1][2]. Instead, doctors use a combination of diet and medication to first “put out the fire” (induction of remission) and then “keep the coals from sparking” (maintenance) [3][4].

Two Main Pillars of Treatment

Most treatment plans focus on either changing what you eat to remove triggers or using medication to calm the immune system’s overactive response [5][6].

1. Dietary Management

Dietary therapy aims to identify and remove the specific foods that trigger your eosinophil buildup [4]. Note: When starting a dietary elimination, it typically takes several weeks (often 4-8 weeks) to see significant symptom improvement and microscopic healing.

  • Elemental Diet: This is the most effective dietary approach. You consume only a special, pre-digested amino acid formula, avoiding all solid food [7][8]. While highly successful at clearing inflammation, it can be difficult to maintain due to its strictness and cost [9][10].
  • Empirical Elimination (e.g., SFED): This involves removing the most common allergy-causing foods, such as milk, wheat, eggs, soy, nuts, and fish/shellfish [7][11]. It is often easier to follow long-term than an elemental diet [12].

2. Pharmacological Treatment (Medications)

Medications are often used when symptoms are severe or when dietary changes aren’t enough [3]. Note: Steroids can act quickly, sometimes improving symptoms within days to a couple of weeks, but they require careful management.

  • Corticosteroids: Drugs like prednisone or prednisolone are the “gold standard” for quickly stopping an acute flare-up [13][6]. However, systemic steroids like prednisone carry significant side effects.
    • Side Effects: Short-term use can cause mood swings, insomnia, and weight gain. Long-term use poses severe risks, including bone density loss (osteoporosis), adrenal suppression, and an increased risk of infections [6].
    • To minimize these systemic risks, doctors often prefer using budesonide, a localized steroid designed to act directly in the gut with fewer side effects throughout the body [14][15].
  • Maintenance Therapy: If your EGE is chronic, you may need long-term “steroid-sparing” options like montelukast to prevent future flares without the side effects of long-term steroids [16][17].

A Framework for Treatment Decisions

Your treatment plan is typically based on the severity of your symptoms and the results of your biopsies [13].

Disease Severity Common Approach
Mild to Moderate Often starts with dietary elimination or localized steroids (budesonide) [4][14].
Severe / Acute Flare Usually requires a short course of systemic corticosteroids (prednisone) to quickly reduce inflammation, followed by a taper [3][13].
Chronic / Refractory May require long-term maintenance meds or consideration for emerging biologic therapies [18][19].

Emerging “Biologic” Therapies

Biologics are a newer class of medication that target specific parts of the immune system. While most are still being studied for EGE, they offer hope for patients who don’t respond to standard treatments [20][21]:

  • Dupilumab: Targets the signals (IL-4 and IL-13) that tell eosinophils to gather in the gut [22][23].
  • Anti-IL-5 (Mepolizumab/Benralizumab): These drugs target the specific messenger that keeps eosinophils alive [19][24].
  • Vedolizumab: A gut-targeted biologic that may prevent eosinophils from entering the digestive tract lining [25][26].

Choosing a treatment is a balance between effectiveness and quality of life. Be open with your care team about your goals—whether that is avoiding steroids, maintaining a diverse diet, or achieving total symptom relief.

Common questions in this guide

What is the best diet for treating Eosinophilic Gastroenteritis (EGE)?
The most effective dietary approach is an elemental diet using a pre-digested formula, but it can be hard to maintain. Many patients find success with a Six-Food Elimination Diet, which removes common triggers like milk, wheat, eggs, soy, nuts, and seafood.
How quickly do steroids work for an EGE flare-up?
Corticosteroids like prednisone can act very quickly to stop an acute flare-up, often improving symptoms within days to a couple of weeks. Because of potential side effects, they are typically used for a short time before transitioning to a maintenance therapy.
What is the difference between prednisone and budesonide for EGE?
Prednisone is a systemic steroid that travels throughout your body and carries higher risks of widespread side effects. Budesonide is a localized steroid designed to act directly in your digestive tract, reducing the risk of side effects in the rest of your body.
Are there targeted therapies or biologics for EGE?
Yes, emerging biologic therapies are being studied for patients who do not respond to standard treatments. Drugs like dupilumab, mepolizumab, and vedolizumab target specific parts of the immune system to prevent eosinophils from gathering in the gut.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my biopsy results and symptoms, do you recommend starting with dietary changes or medication like corticosteroids?
  2. 2.If we use steroids, what is the exact plan for tapering the dose to avoid long-term side effects?
  3. 3.Is budesonide an option for me, as it may have fewer systemic side effects than prednisone?
  4. 4.What criteria will we use to determine if I need a 'steroid-sparing' agent like montelukast or a biologic?
  5. 5.Are there any clinical trials for biologics like dupilumab that I might be eligible for if standard treatments don't work?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Clinical guideline highlight for the hospitalist: Childhood eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis.

    Eckenrode M

    Journal of hospital medicine 2024; (19(8)):709-712 doi:10.1002/jhm.13354.

    PMID: 38563402
  2. 2

    Eosinophilic gastrointestinal disorders, a new epidemic.

    Rossi CM, di Sabatino A

    Current opinion in allergy and clinical immunology 2026; (26(2)):131-137 doi:10.1097/ACI.0000000000001144.

    PMID: 41689485
  3. 3

    Eosinophilic gastrointestinal diseases - Pathogenesis, diagnosis, and treatment.

    Kinoshita Y, Oouchi S, Fujisawa T

    Allergology international : official journal of the Japanese Society of Allergology 2019; (68(4)):420-429 doi:10.1016/j.alit.2019.03.003.

    PMID: 31000445
  4. 4

    Eosinophilic Gastroenteritis with a Relapsing and Remitting Course with Presence of Autoimmune Antibodies.

    Fonseka CL, Nanayakkara S, Singhapura SDAL, et al.

    Case reports in medicine 2020; (2020()):1745834 doi:10.1155/2020/1745834.

    PMID: 32908538
  5. 5

    Evidence-Based and Emerging Diet Recommendations for Small Bowel Disorders.

    Rej A, Potter MDE, Talley NJ, et al.

    The American journal of gastroenterology 2022; (117(6)):958-964 doi:10.14309/ajg.0000000000001764.

    PMID: 35404303
  6. 6

    Eosinophilic gastroenteritis: an uncommon cause of ascites.

    Gómez Otero M, Guerro Moya A, Valdivieso Cortázar E, et al.

    Revista espanola de enfermedades digestivas 2025; (117(11)):689-690 doi:10.17235/reed.2024.10995/2024.

    PMID: 39784683
  7. 7

    Dietary therapy for eosinophilic esophagitis.

    Molina-Infante J, Lucendo AJ

    The Journal of allergy and clinical immunology 2018; (142(1)):41-47 doi:10.1016/j.jaci.2018.02.028.

    PMID: 29522850
  8. 8

    Elemental diet therapy for eosinophilic gastroenteritis and dietary habits.

    Higuchi T, Tokunaga M, Murai T, et al.

    Pediatrics international : official journal of the Japan Pediatric Society 2022; (64(1)):e14894 doi:10.1111/ped.14894.

    PMID: 34157188
  9. 9

    Elimination and elemental diet therapy in eosinophilic oesophagitis.

    Warners MJ, Vlieg-Boerstra BJ, Bredenoord AJ

    Best practice & research. Clinical gastroenterology 2015; (29(5)):793-803 doi:10.1016/j.bpg.2015.06.013.

    PMID: 26552778
  10. 10

    Dietary Therapy for Eosinophilic Esophagitis: Elimination and Reintroduction.

    Kliewer KL, Cassin AM, Venter C

    Clinical reviews in allergy & immunology 2018; (55(1)):70-87 doi:10.1007/s12016-017-8660-1.

    PMID: 29238902
  11. 11

    Illuminating Elimination Diets: Controversies Regarding Dietary Treatment of Eosinophilic Esophagitis.

    Cotton CC, Durban R, Dellon ES

    Digestive diseases and sciences 2019; (64(6)):1401-1408 doi:10.1007/s10620-019-05602-w.

    PMID: 30927211
  12. 12

    Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis.

    Hirano I, Furuta GT

    Gastroenterology 2020; (158(4)):840-851 doi:10.1053/j.gastro.2019.09.052.

    PMID: 31836530
  13. 13

    Eosinophilic Gastrointestinal Diseases: The Pathogenesis, Diagnosis, and Treatment.

    Kinoshita Y, Yahata S, Oouchi S

    Internal medicine (Tokyo, Japan) 2023; (62(1)):1-10 doi:10.2169/internalmedicine.8417-21.

    PMID: 34670903
  14. 14

    Retrospective study of budesonide in children with eosinophilic gastroenteritis.

    Fang S, Song Y, Zhang S, Li C

    Pediatric research 2019; (86(4)):505-509 doi:10.1038/s41390-019-0444-2.

    PMID: 31141816
  15. 15

    Eosinophilic Gastroenteritis-associated Duodenal Ulcer Successfully Treated with Crushed Budesonide.

    Kubo K, Kimura N, Mabe K, et al.

    Internal medicine (Tokyo, Japan) 2020; (59(18)):2249-2254 doi:10.2169/internalmedicine.4706-20.

    PMID: 32536650
  16. 16

    Eosinophilic gastroenteritis in a 45-year-old female with epigastric abdominal pain: a rare case report.

    Mousa A, Daas L, Hababeh MN, et al.

    Annals of medicine and surgery (2012) 2026; (88(3)):2434-2437 doi:10.1097/MS9.0000000000004793.

    PMID: 41789234
  17. 17

    Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review.

    El-Alali EA, Abukhiran IM, Alhmoud TZ

    BMC gastroenterology 2021; (21(1)):279 doi:10.1186/s12876-021-01854-x.

    PMID: 34238222
  18. 18

    Eosinophilic Gastroenteritis: Using Presenting Findings to Predict Disease Course.

    Havlichek D, Choung RS, Murray JA

    Clinical and translational gastroenterology 2021; (12(10)):e00394 doi:10.14309/ctg.0000000000000394.

    PMID: 34620754
  19. 19

    The Unusual Clinical Presentation of Eosinophilic Gastroenteritis and Its Response to Mepolizumab: Two Case Reports.

    Kiblawi MA, Malik T, Edan MM

    Cureus 2024; (16(10)):e72589 doi:10.7759/cureus.72589.

    PMID: 39610640
  20. 20

    Future therapies for eosinophilic gastrointestinal disorders.

    Pesek RD, Gupta SK

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2020; (124(3)):219-226 doi:10.1016/j.anai.2019.11.018.

    PMID: 31778820
  21. 21

    Advancements in Biologic Therapies for Eosinophilic Gastrointestinal Diseases: A Comprehensive Review.

    Melhem RA, Hassoun Y

    Immunology and allergy clinics of North America 2024; (44(4)):615-627 doi:10.1016/j.iac.2024.07.002.

    PMID: 39389713
  22. 22

    A Case Series on the Use of Dupilumab for Treatment of Refractory Eosinophilic Gastrointestinal Disorders.

    Patel N, Goyal A, Thaker A, et al.

    Journal of pediatric gastroenterology and nutrition 2022; (75(2)):192-195 doi:10.1097/MPG.0000000000003512.

    PMID: 35666881
  23. 23

    Successful use of dupilumab for egg-induced eosinophilic gastroenteritis with duodenal ulcer: a pediatric case report and review of literature.

    Tsuge M, Shigehara K, Uda K, et al.

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2023; (19(1)):103 doi:10.1186/s13223-023-00859-3.

    PMID: 38053199
  24. 24

    Effect of Biologics against Interleukin-5 Administered to Patients with Eosinophilic Gastroenteritis.

    Miyaguchi K, Matsumoto H, Shiomi R, et al.

    Internal medicine (Tokyo, Japan) 2025; (64(19)):2846-2851 doi:10.2169/internalmedicine.5029-24.

    PMID: 40090714
  25. 25

    Combined eosinophilic gastroenteritis and ulcerative colitis successfully treated by vedolizumab: a case report.

    Takedomi H, Fukuda K, Inoue S, et al.

    Intestinal research 2025; (23(1)):107-111 doi:10.5217/ir.2024.00013.

    PMID: 39205502
  26. 26

    Climbing New Mountains: How Antibodies Blocking α4β7 Integrins Tamed Eosinophilic Inflammation of the Intestinal Tract.

    Olbrich CL, Simerly L, de Zoeten EF, et al.

    Digestive diseases and sciences 2019; (64(8)):2068-2071 doi:10.1007/s10620-019-05706-3.

    PMID: 31273593

This page provides educational information about EGE treatment pathways, including diet and medication. Always consult your gastroenterologist or care team to design a personalized treatment plan.

Get notified when new evidence is published on Eosinophilic gastroenteritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.